In children with infantile spasms, cosyntropin achieved composite resolution in 9/12 (75%) versus 1/9 (11%) with vigabatrin (P < .01).
In plain wordsIn children with infantile spasms, cosyntropin improved combined seizure and EEG resolution more than vigabatrin.
- Peptide
- Cosyntropin
- Outcome
- IncreaseResolution of hypsarhythmia and clinical spasms
- Study
n = 21
- Comparator
- Vigabatrin
- Analysis
- Primary
- Outcome group
- Seizures · Nervous system and cognition
- Studied dose
- Dose not stated
Measurements
- Resolution of hypsarrhythmia and clinical spasms at day 14
- 75%
- cosyntropin, 9 of 12
- Resolution of hypsarrhythmia and clinical spasms at day 14
- 11%
- vigabatrin, 1 of 9
- Difference, cosyntropin vs vigabatrin
- 64%
- 95% CI 21 to 82; P < .01
Source sentences
Resolution of both hypsarhythmia and clinical spasms was achieved in in 9 of 12 participants (75%) treated with cosyntropin, 1/9 (11%) vigabatrin, and 5/13 (38%) cosyntropin and vigabatrin combined.
2 context sentences(design, population, supporting numbers)
The primary comparison of cosyntropin versus vigabatrin was significant (64% [95% confidence interval 21, 82], P < .01).
Children (2 months to 2 years) with new-onset infantile spasms syndrome and hypsarhythmia were randomized into 3 arms: cosyntropin, vigabatrin, and cosyntropin and vigabatrin combined.